Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Debt to Equity (2017 - 2026)

Ani Pharmaceuticals' Debt to Equity history spans 11 years, with the latest figure at $0.57 for Q4 2025.

  • On a quarterly basis, Debt to Equity fell 27.5% to $0.57 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.57, a 27.5% decrease, with the full-year FY2025 number at $0.57, down 27.5% from a year prior.
  • Debt to Equity hit $0.57 in Q4 2025 for Ani Pharmaceuticals, down from $0.62 in the prior quarter.
  • Over the last five years, Debt to Equity for ANIP hit a ceiling of $287157.0 in Q1 2022 and a floor of -$91.67 in Q4 2021.
  • Historically, Debt to Equity has averaged $72748.4 across 5 years, with a median of $1.06 in 2021.
  • Biggest five-year swings in Debt to Equity: surged 31891934.69% in 2022 and later crashed 163.96% in 2023.
  • Tracing ANIP's Debt to Equity over 5 years: stood at -$91.67 in 2021, then surged by 311744.33% to $285669.0 in 2022, then crashed by 50.0% to $142834.5 in 2023, then plummeted by 100.0% to $0.79 in 2024, then fell by 27.5% to $0.57 in 2025.
  • Business Quant data shows Debt to Equity for ANIP at $0.57 in Q4 2025, $0.62 in Q3 2025, and $157350.0 in Q2 2025.